Abstract 1: Association of antithrombin levels with efficacy of fitusiran prophylaxis in people with hemophilia A or B with and without inhibitors: a predictive modeling approachAbstract 2: Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 studyAbstract 3: Long-term efficacy of marstacimab in participants with severe hemophilia A or B without inhibitors

Abstract 1: Association of antithrombin levels with efficacy of fitusiran prophylaxis in people with hemophilia A or B with and without inhibitors: a predictive modeling approach Abstract 2: Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study Abstract 3: Long-term efficacy of marstacimab in participants with severe hemophilia A or B without inhibitors

A Focus on Rebalancing Agents

The treatment of persons with hemophilia continues to evolve, with important advancements that address limitations with factor replacement such as diminished efficacy in patients with inhibitors and the burden of frequent intravenous administration. This 30-minute activity delves into the latest research presented at ISTH 2025, highlighting rebalancing agents and factor VIII mimetics. In addition to discussing details of each trial, Dr. von Drygalski shares her thoughts about its importance and relevance to clinical practice.

Share A Focus on Rebalancing Agents

Sign up to save your podcasts

A Focus on Rebalancing Agents

A Focus on Rebalancing Agents